UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Renal disease associated with hepatitis B virus infection

Authors
Tak-Mao Chan, MD, FRCP
Anna SF Lok, MD
Section Editors
Richard J Glassock, MD, MACP
Martin S Hirsch, MD
Deputy Editor
Albert Q Lam, MD

INTRODUCTION

Infection with hepatitis B virus (HBV) may be associated with a variety of renal diseases [1,2]. The three most common types of renal disease resulting from HBV infection are:

Membranous glomerulonephritis

Membranoproliferative glomerulonephritis (MPGN)

Polyarteritis nodosa (PAN)

In addition, HBV infection has been associated with mesangial proliferative glomerulonephritis, IgA nephropathy, and amyloidosis.

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Jan 11 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37:663.
  2. Lai KN, Lai FM. Clinical features and the natural course of hepatitis B virus-related glomerulopathy in adults. Kidney Int Suppl 1991; 35:S40.
  3. Levy M, Chen N. Worldwide perspective of hepatitis B-associated glomerulonephritis in the 80s. Kidney Int Suppl 1991; 35:S24.
  4. Xu H, Sun L, Zhou LJ, et al. The effect of hepatitis B vaccination on the incidence of childhood HBV-associated nephritis. Pediatr Nephrol 2003; 18:1216.
  5. Liao MT, Chang MH, Lin FG, et al. Universal hepatitis B vaccination reduces childhood hepatitis B virus-associated membranous nephropathy. Pediatrics 2011; 128:e600.
  6. Takekoshi Y, Tochimaru H, Nagata Y, Itami N. Immunopathogenetic mechanisms of hepatitis B virus-related glomerulopathy. Kidney Int Suppl 1991; 35:S34.
  7. Lai KN, Li PK, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med 1991; 324:1457.
  8. Lai KN, Ho RT, Tam JS, Lai FM. Detection of hepatitis B virus DNA and RNA in kidneys of HBV related glomerulonephritis. Kidney Int 1996; 50:1965.
  9. Hong L, Zhang J, Min J, et al. A role for MHBst167/HBx in hepatitis B virus-induced renal tubular cell apoptosis. Nephrol Dial Transplant 2010; 25:2125.
  10. Diao Z, Ding J, Yin C, et al. Purified hepatitis B virus induces human mesangial cell proliferation and extracellular matrix expression in vitro. Virol J 2013; 10:300.
  11. Li P, Wei RB, Tang L, et al. Clinical and pathological analysis of hepatitis B virus-related membranous nephropathy and idiopathic membranous nephropathy. Clin Nephrol 2012; 78:456.
  12. Qin W, Beck LH Jr, Zeng C, et al. Anti-phospholipase A2 receptor antibody in membranous nephropathy. J Am Soc Nephrol 2011; 22:1137.
  13. Guillevin L, Lhote F. Treatment of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1998; 41:2100.
  14. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alpha-interferon. Kidney Int 1995; 47:225.
  15. Perez GO, Pardo V, Fletcher M. Renal involvement in essential mixed cryoglobulinemia. Am J Kidney Dis 1987; 10:276.
  16. Enríquez R, Sirvent AE, Andrada E, et al. Cryoglobulinemic glomerulonephritis in chronic hepatitis B infection. Ren Fail 2010; 32:518.
  17. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus. A prospective study with long-term observation of 41 patients. Medicine (Baltimore) 1995; 74:238.
  18. KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209. http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO-GN-Guideline.pdf (Accessed on December 23, 2013).
  19. Lisker-Melman M, Webb D, Di Bisceglie AM, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: treatment with recombinant human alpha-interferon. Ann Intern Med 1989; 111:479.
  20. Conjeevaram HS, Hoofnagle JH, Austin HA, et al. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa. Gastroenterology 1995; 109:540.
  21. Chung DR, Yang WS, Kim SB, et al. Treatment of hepatitis B virus associated glomerulonephritis with recombinant human alpha interferon. Am J Nephrol 1997; 17:112.
  22. Bhimma R, Coovadia HM, Kramvis A, et al. Treatment of hepatitis B virus-associated nephropathy in black children. Pediatr Nephrol 2002; 17:393.
  23. Fabrizi F, Dixit V, Martin P. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis. Aliment Pharmacol Ther 2006; 24:781.
  24. Wen YK, Chen ML. Remission of hepatitis B virus-associated membranoproliferative glomerulonephritis in a cirrhotic patient after lamivudine therapy. Clin Nephrol 2006; 65:211.
  25. Kruger M, Böker KH, Zeidler H, Manns MP. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b. J Hepatol 1997; 26:935.
  26. Avşar E, Savaş B, Tözün N, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with interferon alpha as first-line therapy. J Hepatol 1998; 28:525.
  27. Simsek H, Telatar H. Successful treatment of hepatitis B virus-associated polyarteritis nodosa by interferon alpha alone. J Clin Gastroenterol 1995; 20:263.
  28. Wenderfer SE. Viral-associated glomerulopathies in children. Pediatr Nephrol 2015; 30:1929.
  29. Tang S, Lai FM, Lui YH, et al. Lamivudine in hepatitis B-associated membranous nephropathy. Kidney Int 2005; 68:1750.
  30. Sun IO, Hong YA, Park HS, et al. Experience of anti-viral therapy in hepatitis B-associated membranous nephropathy, including Lamivudine-resistant strains. Korean J Intern Med 2012; 27:411.
  31. Lin CY, Lo SC. Treatment of hepatitis B virus-associated membranous nephropathy with adenine arabinoside and thymic extract. Kidney Int 1991; 39:301.
  32. Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990; 54:12.
  33. Sayarlioglu H, Erkoc R, Dogan E, et al. Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication. Ann Pharmacother 2005; 39:573.
  34. Mitka M. FDA: Increased HBV reactivation risk with ofatumumab or rituximab. JAMA 2013; 310:1664.
  35. Guillevin L, Pagnoux C. Indications of plasma exchanges for systemic vasculitides. Ther Apher Dial 2003; 7:155.
  36. Wicki J, Olivieri J, Pizzolato G, et al. Successful treatment of polyarteritis nodosa related to hepatitis B virus with a combination of lamivudine and interferon alpha. Rheumatology (Oxford) 1999; 38:183.
  37. Guillevin L, Lhote F, Sauvaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis 1994; 53:334.
  38. Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum 2004; 51:482.
  39. Janssen HL, van Zonneveld M, van Nunen AB, et al. Polyarteritis nodosa associated with hepatitis B virus infection. The role of antiviral treatment and mutations in the hepatitis B virus genome. Eur J Gastroenterol Hepatol 2004; 16:801.
  40. Leib ES, Restivo C, Paulus HE. Immunosuppressive and corticosteroid therapy of polyarteritis nodosa. Am J Med 1979; 67:941.
  41. Guillevin L, Mahr A, Callard P, et al. Hepatitis B virus-associated polyarteritis nodosa: clinical characteristics, outcome, and impact of treatment in 115 patients. Medicine (Baltimore) 2005; 84:313.
  42. Fernanda F, Serena C, Giustina R, et al. Mycophenolate mofetil treatment in two children with severe polyarteritis nodosa refractory to immunosuppressant drugs. Rheumatol Int 2012; 32:2215.
  43. Néel A, Masseau A, Hervier B, et al. Life-threatening hepatitis C virus-associated polyarteritis nodosa successfully treated by rituximab. J Clin Rheumatol 2011; 17:439.